Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

Hsp90 inhibitor NXD30001 as a potential therapeutic agent in Amyotrophic Lateral Sclerosis (ALS)

FY 2009-10

Summary
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease) is a fatal neurodegenerative disease usually leading to loss of life within two to five years from diagnosis. Currently, there is no cure or effective treatment for ALS. The disease is characterized by death of motor neurons, neurons in the brain and spinal cord responsible for voluntary and reflex control of movement. Patients experience progressive weakness and atrophy of the musculature, resulting in paralysis and ultimately death from inability to breathe. ALS occurs in forms that run in families (familial) and those of unknown cause (sporadic), but these forms share common clinical features and neuropathological abnormalities, including rock-like inclusions of aggregated protein in diseased motor neurons. When proteins are synthesized in cells, they take on a particular shape required for their normal function. Misfolding of proteins due to genetic mutations (familial ALS) or environmental conditions causes them to become toxic, and to precipitate in cells. Our lab has shown that increasing production of protein chaperones, which help disease-causing proteins fold properly, is highly neuroprotective in a culture model of familial ALS. This was accomplished using a class of molecules called Hsp90 inhibitors; however, currently available drugs do not readily penetrate into the nervous system and are too toxic for long-term therapeutic use. The Durham lab has teamed up with NexGenix Pharmaceuticals to test their novel compounds that penetrate into the brain and spinal cord and show an improved safety profile. My project is to test the lead compound, NXD30001, for its ability to prevent protein aggregation and prolong motor neuron survival in the tissue culture model of ALS, and to delay the onset and progression of ALS-like symptoms in a mouse model. The goal is to develop a drug that significantly delays progression of ALS and other neurodegenerative diseases and improves the quality of life of patients.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
197154
Name
Cha Jieun R
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Hsp90 inhibitor NXD30001 as a potential therapeutic agent in Amyotrophic Lateral Sclerosis (ALS)
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Amyotrophic Lateral Sclerosis; Cellular Stress Responses; Fluorometric Imaging; Hsp90 Inhibitor; Immunocytochemistry; Intranuclear Microinjection; Motor Neuron Disease; Neurodegenerative Disease; Preclinical Testing; Primary Culture Model
Abstract
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease) is a fatal neurodegenerative disease usually leading to loss of life within two to five years from diagnosis. Currently, there is no cure or effective treatment for ALS. The disease is characterized by death of motor neurons, neurons in the brain and spinal cord responsible for voluntary and reflex control of movement. Patients experience progressive weakness and atrophy of the musculature, resulting in paralysis and ultimately death from inability to breathe. ALS occurs in forms that run in families (familial) and those of unknown cause (sporadic), but these forms share common clinical features and neuropathological abnormalities, including rock-like inclusions of aggregated protein in diseased motor neurons. When proteins are synthesized in cells, they take on a particular shape required for their normal function. Misfolding of proteins due to genetic mutations (familial ALS) or environmental conditions causes them to become toxic, and to precipitate in cells. Our lab has shown that increasing production of protein chaperones, which help disease-causing proteins fold properly, is highly neuroprotective in a culture model of familial ALS. This was accomplished using a class of molecules called Hsp90 inhibitors; however, currently available drugs do not readily penetrate into the nervous system and are too toxic for long-term therapeutic use. The Durham lab has teamed up with NexGenix Pharmaceuticals to test their novel compounds that penetrate into the brain and spinal cord and show an improved safety profile. My project is to test the lead compound, NXD30001, for its ability to prevent protein aggregation and prolong motor neuron survival in the tissue culture model of ALS, and to delay the onset and progression of ALS-like symptoms in a mouse model. The goal is to develop a drug that significantly delays progression of ALS and other neurodegenerative diseases and improves the quality of life of patients.
Competitiondate
200911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cha, Jieun R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
McGill University - $150,000 Grant (2009-10) | Canada Spends